Correspondence

Early noninvasive ventilation failure in COPD with acute on chronic respiratory failure

To the Editors:

Noninvasive ventilation (NIV) has proven to be of great interest in the management of acute respiratory failure (ARF) due to exacerbations of chronic obstructive pulmonary disease (COPD), with an improvement in arterial blood gas tensions and respiratory frequency usually observed 1–6 h after initiation [1, 2]. We describe an unusual and reversible condition of early NIV failure as follows.

The patient was a 72-yr-old male with chronic respiratory failure from COPD, successfully treated with nocturnal bilevel pressure NIV for 20 months. He was hospitalised in our respiratory intensive care unit (CHU de Rouen, Hôpital de Bois-Guillaume, Rouen, France) for ARF (pH=7.26; arterial carbon dioxide tension (P_a,CO_2) 11.4 kPa; arterial oxygen tension (P_a,O_2)/inspiratory oxygen fraction (F_I,O_2) 338). The patient presented with bilateral wheezing, encephalopathy and gaseous abdominal distension. Standard medical treatment associated with NIV failed to improve the patient’s condition, despite different settings with pressure-preset and flow-preset ventilatory modes, and careful management with facial and nasal masks. Five hours after admission, the patient’s condition worsened (pH=7.12; P_a,CO_2 19.2 kPa; P_a,O_2/F_I,O_2 115). Intubation was then performed, subsequently revealing a laryngeal vestibule carcinoma, partially obstructing the glottis aperture. After tumoural laser resection, the patient was successfully weaned, extubated and then discharged home with his previous NIV treatment.

Early NIV failure in COPD with ARF may be ascribed to the patient’s clinical status, such as bronchial hypersecretion, deterioration in medical condition, pneumothorax, haemodynamic instability, severe encephalopathy or gastric distension. Technical ventilator-associated factors could also account for early NIV failure, such as inadequate settings and/or ventilatory mode, inadequate inspiratory and/or expiratory triggering, deleterious leaks, excessive dead space and rebreathing. Preliminary data suggest that patient–ventilator asynchronism and NIV failure could also result from underestimated high nasal and/or upper airway resistances, particularly reflex glottic narrowing [3]. In this respect, upper airway tumours may cause progressive airway obstruction, can mimic a COPD exacerbation and lead to difficulties during NIV, except if their presence is clinically suspected by a stridor. Indeed, NIV is contraindicated in this latter situation, and the patients should be intubated. In patients with ARF treated by invasive mechanical ventilation, local tumoural resection by bronchoscopic intervention has been shown to be associated with successful weaning in the majority of cases and to be a cost-saving approach [4].

During chronic obstructive pulmonary disease exacerbation requiring noninvasive ventilation, we suggest that an unexplained early noninvasive ventilation failure should lead to an evaluation of the integrity of the extra- and intrathoracic upper airways before or during the mandatory intubation procedure. Fibreoptic bronchoscopy via a facial mask may facilitate an early diagnosis, but still needs to be evaluated for patients with this condition [5].

A. Cuvelier, L.C. Molano and J-F. Muir
Respiratory and Intensive Care Medicine, CHU de Rouen, Hôpital de Bois-Guillaume, Rouen, France.

References

the diagnostic criteria of impaired antibody response. There are no universal criteria for adequate antibody response to polysaccharides and each laboratory should establish its own [2]. This is particularly important because of the therapeutic implications. Treatment of symptomatic patients with a lack of antibody response is performed with periodic administration of intravenous immunoglobulins (Ig) at a high cost, dependent on healthcare centres and potential side-effects [3]. For this reason, strict diagnostic criteria must be established.

It is interesting to note that van Kessel et al. [1] used different criteria for the response with total antibodies to the serotypes 3, 4 and 9V, in which the post-vaccination titre should be $\geq 20$ U·mL$^{-1}$ with at least a two-fold increase for two of the three serotypes, and to the isotypes IgA and IgG2 of the six serotypes studied, in which response was defined individually for each serotype as post-immunisation concentrations $>50$ U·mL$^{-1}$ and an isotype responder had to have a positive IgA and/or IgG2 response to more than four out of six of the serotypes. The reason for these criteria are not clear and should be based on the knowledge of the response of healthy individuals. With their criteria, a patient could potentially be classified as a reponder if he/she presented post-immunisation concentrations of IgA $>50$ U·mL$^{-1}$ to five of the six serotypes, but with low concentrations of IgG2 to all serotypes. The clinical meaning of the antibody response with the different isotypes is not equivalent. As an example, the clinical manifestations of patients with IgA deficiency in the form of respiratory infections are due, in great part, to the possible association of an IgG-subclass deficiency, particularly IgG2 deficiency [4, 5].

The usefulness of their response criteria can be validated, at least in part, with the clinical characteristics of the responder and nonresponder patients. There were very few, nonsignificant and probably not clinically meaningful differences between the group of responders and nonresponders. Only the number of resected segments was significantly different in both groups, but it would be interesting to see the number of patients requiring surgery in both groups. This result could be subjected to possible bias in a case in which a single severe patient requiring extensive surgery was included in the group of nonresponders [1].

The next query refers to the meaning of the lack of response to individual serotypes of \textit{S. pneumoniae}. The immunological interest is clear, but the clinical meaning is controversial. It would be very informative to know the clinical characteristics of the four patients classified as nonresponders by showing post-vaccination total antibody titres below the threshold and comparing them with the remaining 22 patients [1]. In contrast, the lack of response with a particular isotype of Ig to one or some individual serotypes can potentially be less harmful than the lack of response with total IgG or IgG2 to all serotypes considered together. This last condition may be a marker of a more profound impairment in antibody response and, if this impairment is also observed against conjugated polysaccharides such as the \textit{Haemophilus influenzae} type B (Hib) vaccine in a patient with recurrent respiratory infections, it is a criterion for Ig replacement therapy [6]. This lack of response to both vaccines is a characteristic of patients with a severe immune impairment [6]; however, it is not at all clear that the lack of response restricted to one or more unconjugated polysaccharides deserves treatment with Ig. van Kessel et al. [1] mention that without the study of the response to different pneumococcal serotypes with both isotypes, IgA and/or IgG2, 11 out of 15 so-called nonresponders would have been missed, but there is no convincing clinical or immunological evidence that these individuals had a worse prognosis and were, therefore, candidates for Ig replacement therapy.

By studying a group of healthy adults and a group of patients with humoral immunodeficiencies characterised by defective antibody formation, Rodrigo and coworkers [6, 7] were able to establish a response criteria to both the pneumococcal and the conjugated Hib vaccines. It was observed that not all healthy individuals responded adequately to either vaccine with all serotypes, but, conversely, no healthy subject presented a lack of response to both vaccines [6]. In contrast, none of the patients with humoral immunodeficiencies responded to either vaccine. Therefore, it was shown that evaluation of the antibody response to both the conjugated and nonconjugated vaccine allows the diagnosis of the humoral immunodeficiency characterised by a lack of antibody response to polysaccharides to be established, and permits the selection of patients as candidates to receive Ig therapy.

By using these criteria based on lack of response to both vaccines, we could observe an antibody-production deficiency with normal IgG levels in 11% of a group of 107 patients with bronchiectasis of unknown aetiology. The nonresponders had a significantly higher incidence of otitis media, lower serum IgG2 subclass levels and lower pre-immunisation antibody titres to \textit{S. pneumoniae} and Hib, and had recurrent pneumonia more frequently (in this latter case, differences were not significant due to the low number of nonresponders) [8], similar to the first case described by Ambrosino et al. [9].

We totally agree that a sizeable fraction of patients with bronchiectasis of unknown cause can now be classified as bronchiectasis associated with polysaccharide antibody-response deficiency [1, 8, 10, 11]. However, before this diagnosis can be established and substitution therapy with immunoglobulins can be indicated, comprehensive immunological evaluation is mandatory. This evaluation should include analysis of antibody response to a conjugated and unconjugated vaccine, and response criteria must be defined based on the response of a healthy adult population [6, 7].

**REFERENCES**


Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension

To the Editors:

HOEPER et al. [1] have produced an interesting report of their clinical experience of combined therapy with bosentan and sildenafil in patients with idiopathic pulmonary arterial hypertension. Whilst it is true that the relatively scant literature supporting the use of phosphodiesterase-5 inhibitors is centred around sildenafil, its relatively short duration of action requires the use of a thrice-daily regime. This has significant implications for compliance and, since treatment is continual, has large implications in the cost of treatment. It would be more logical to use a long-acting phosphodiesterase-5 inhibitor, and, with the advent of tadalafil, once-daily treatment becomes possible.

Here, we report our experience with a combination of bosentan and tadalafil in a 42-yr-old male with idiopathic pulmonary hypertension who had documented poor compliance with nebulised iloprost. Sildenafil 25 mg t.d.s. was added to bosentan, following a clinical deterioration and the finding of an estimated pulmonary artery systolic pressure of 130 mmHg, and this caused a fall in pulmonary artery pressure to 50 mmHg. Treatment with sildenafil was stopped 1 month later at another centre, and the pulmonary artery systolic pressure increased to 100 mmHg. Subsequently, sildenafil was restarted in combination with bosentan, and exercise tolerance doubled. After 3 months of combination treatment, the issue of compliance was raised by the patient and it was decided to substitute tadalafil 20 mg once daily for the sildenafil. The patient has continued on tadalafil for 9 months with an excellent symptomatic response. The last estimated pulmonary artery pressure was 61 mmHg.

A.H. Morice, S. Mulrennan and A. Clark
Division of Academic Medicine, University of Hull, Castle Hill Hospital, Hull, UK.

REFERENCES

From the authors:

I am grateful for the comments by A.H. Morice and coworkers, although their case report leaves several questions unanswered. More information than just the systolic pulmonary artery pressure is needed to appraise the haemodynamic response to tadalafil. One wonders whether this patient ever underwent pulmonary vasoreactivity testing. With such a

Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension

To the Editors:

HOEPER et al. [1] have produced an interesting report of their clinical experience of combined therapy with bosentan and sildenafil in patients with idiopathic pulmonary arterial hypertension. Whilst it is true that the relatively scant literature supporting the use of phosphodiesterase-5 inhibitors is centred around sildenafil, its relatively short duration of action requires the use of a thrice-daily regime. This has significant implications for compliance and, since treatment is continual, has large implications in the cost of treatment. It would be more logical to use a long-acting phosphodiesterase-5 inhibitor, and, with the advent of tadalafil, once-daily treatment becomes possible.

Here, we report our experience with a combination of bosentan and tadalafil in a 42-yr-old male with idiopathic pulmonary hypertension who had documented poor compliance with nebulised iloprost. Sildenafil 25 mg t.d.s. was added to bosentan, following a clinical deterioration and the finding of an estimated pulmonary artery systolic pressure of 130 mmHg, and this caused a fall in pulmonary artery pressure to 50 mmHg. Treatment with sildenafil was stopped 1 month later at another centre, and the pulmonary artery systolic pressure increased to 100 mmHg. Subsequently, sildenafil was restarted in combination with bosentan, and exercise tolerance doubled. After 3 months of combination treatment, the issue of compliance was raised by the patient and it was decided to substitute tadalafil 20 mg once daily for the sildenafil. The patient has continued on tadalafil for 9 months with an excellent symptomatic response. The last estimated pulmonary artery pressure was 61 mmHg.

A.H. Morice, S. Mulrennan and A. Clark
Division of Academic Medicine, University of Hull, Castle Hill Hospital, Hull, UK.

REFERENCES

From the authors:

I am grateful for the comments by A.H. Morice and coworkers, although their case report leaves several questions unanswered. More information than just the systolic pulmonary artery pressure is needed to appraise the haemodynamic response to tadalafil. One wonders whether this patient ever underwent pulmonary vasoreactivity testing. With such a